BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20145548)

  • 1. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28.
    Rosenblatt J; Wu Z; Vasir B; Zarwan C; Stone R; Mills H; Friedman T; Konstantinopoulos PA; Spentzos D; Ghebremichael M; Stevenson K; Neuberg D; Levine JD; Joyce R; Tzachanis D; Boussiotis V; Kufe D; Avigan D
    J Immunother; 2010; 33(2):155-66. PubMed ID: 20145548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.
    Vasir B; Wu Z; Crawford K; Rosenblatt J; Zarwan C; Bissonnette A; Kufe D; Avigan D
    J Immunol; 2008 Jul; 181(1):808-21. PubMed ID: 18566447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human autologous dendritic cell-glioma fusions: feasibility and capacity to stimulate T cells with proliferative and cytolytic activity.
    Sloan AE; Parajuli P
    J Neurooncol; 2003; 64(1-2):177-83. PubMed ID: 12952298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.
    Rosenblatt J; Glotzbecker B; Mills H; Vasir B; Tzachanis D; Levine JD; Joyce RM; Wellenstein K; Keefe W; Schickler M; Rotem-Yehudar R; Kufe D; Avigan D
    J Immunother; 2011 Jun; 34(5):409-18. PubMed ID: 21577144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells.
    Koido S; Tanaka Y; Tajiri H; Gong J
    Vaccine; 2007 Mar; 25(14):2610-9. PubMed ID: 17239504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.
    Koido S; Hara E; Homma S; Torii A; Mitsunaga M; Yanagisawa S; Toyama Y; Kawahara H; Watanabe M; Yoshida S; Kobayashi S; Yanaga K; Fujise K; Tajiri H
    J Immunol; 2007 Jan; 178(1):613-22. PubMed ID: 17182602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
    Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
    Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
    Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
    J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.
    Brimnes MK; Gang AO; Donia M; Thor Straten P; Svane IM; Hadrup SR
    Cancer Immunol Immunother; 2012 Aug; 61(8):1221-31. PubMed ID: 22237888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells.
    Koido S; Hara E; Torii A; Homma S; Toyama Y; Kawahara H; Ogawa M; Watanabe M; Yanaga K; Fujise K; Gong J; Toda G
    Int J Cancer; 2005 Nov; 117(4):587-95. PubMed ID: 15945098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells.
    Schmitt S; Tahk S; Lohner A; Hänel G; Maiser A; Hauke M; Patel L; Rothe M; Josenhans C; Leonhardt H; Griffioen M; Deiser K; Fenn NC; Hopfner KP; Subklewe M
    Front Immunol; 2020; 11():602802. PubMed ID: 33281829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28.
    Kroesen BJ; Bakker A; van Lier RA; The HT; de Leij L
    Cancer Res; 1995 Oct; 55(19):4409-15. PubMed ID: 7545540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.
    Wang B; Zhu Y; Zhang JJ; Chen Z; Liang WB; Xu ZK
    Asian Pac J Cancer Prev; 2011; 12(11):2811-7. PubMed ID: 22393946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.
    Kalady MF; Onaitis MW; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
    J Surg Res; 2004 Jan; 116(1):24-31. PubMed ID: 14732346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells.
    Hsu FJ; Komarovskaya M
    J Immunother; 2002; 25(6):455-68. PubMed ID: 12439343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes.
    Koido S; Homma S; Okamoto M; Namiki Y; Takakura K; Takahara A; Odahara S; Tsukinaga S; Yukawa T; Mitobe J; Matsudaira H; Nagatsuma K; Uchiyama K; Kajihara M; Arihiro S; Imazu H; Arakawa H; Kan S; Komita H; Ito M; Ohkusa T; Gong J; Tajiri H
    PLoS One; 2013; 8(3):e59280. PubMed ID: 23555011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD69 does not affect the extent of T cell priming.
    Alari-Pahissa E; Notario L; Lorente E; Vega-Ramos J; Justel A; López D; Villadangos JA; Lauzurica P
    PLoS One; 2012; 7(10):e48593. PubMed ID: 23119065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.